TEST CATALOG ORDERING & RESULTS SPECIMEN HANDLING CUSTOMER SERVICE EDUCATION & INSIGHTS
Test Catalog

Test ID: MPCDS    
mSMART, Plasma Cell Proliferative Disorder, FISH, Bone Marrow

Useful For Suggests clinical disorders or settings where the test may be helpful

Aiding in the diagnosis of new cases of multiple myeloma or other plasma cell proliferative disorders as a part of a profile

 

Identifying prognostic markers based on the anomalies found

 

This test should not be used to track the progression of disease.

Reflex Tests Lists tests that may or may not be performed, at an additional charge, depending on the result and interpretation of the initial tests.

Test IDReporting NameAvailable SeparatelyAlways Performed
_PBCTProbe, +2No, (Bill Only)No
_PADDProbe, +1No, (Bill Only)No
_PB02Probe, +2No, (Bill Only)No
_PB03Probe, +3No, (Bill Only)No
_IL25Interphases, <25No, (Bill Only)No
_I099Interphases, 25-99No, (Bill Only)No
_I300Interphases, >=100 No, (Bill Only)No

Testing Algorithm Delineates situations when tests are added to the initial order. This includes reflex and additional tests.

This test is only orderable as part of a profile, based on the flow cytometric analysis and presence of 0.1% or greater monotypic plasma cells. For more information see MSMRT / Mayo Algorithmic Approach for Stratification of Myeloma and Risk-Adapted Therapy Report, Bone Marrow.

 

This test is designed for diagnostic specimens from patients with multiple myeloma or other plasma cell proliferative disorders.

 

This test includes a charge for application of the first probe set (2 fluorescence in situ hybridization: FISH probes) and professional interpretation of results. Additional charges will be incurred for all reflex probes performed. Analysis charges will be incurred based on the number of cells analyzed per probe set. If no cells are available for analysis, no analysis charges will be incurred.

 

For diagnostic samples, all probes in the initial panel will be evaluated if sufficient plasma cells are identified. The initial panel includes testing for the following abnormalities using the probes listed:

17p-, TP53/D17Z1

1q gain, TP73/1q22

14q32 rearrangement, IGH

t(11;14), CCND1/IGH

8q24.1 rearrangement, MYC

-13/13q-, RB1/LAMP1

+9/+15, D9Z1/D15Z4

+3/+7, D3Z1/D7Z1

Based on the results from the initial panel, reflex testing may be performed to identify the following abnormalities using the probes listed:

t(14;16)(q32;q23) IGH/MAF

t(4;14)(p16.3;q32) FGFR3/IGH

t(14;20)(q32;q12) IGH/MAFB

t(6;14)(p21;q32) CCND3/IGH

 

For follow-up samples, only TP73/1q22, TP53/D17Z1 and MYC probes along with a single probe that was abnormal in a previous study will be tested. If a previous sample was uninformative due to an insufficient number of plasma cells, analysis will begin with the initial panel (if sufficient plasma cells are identified).

 

Initial screening will be performed to determine if sufficient plasma cells are present within the provided specimen. If the standard algorithm is not desired, indicate which probes should be used.

Method Name A short description of the method used to perform the test

Only orderable as part of a profile. For more information see MSMRT / Mayo Algorithmic Approach for Stratification of Myeloma and Risk-Adapted Therapy Report, Bone Marrow.

 

Fluorescence In Situ Hybridization (FISH)

NY State Available Indicates the status of NY State approval and if the test is orderable for NY State clients.

Yes

Reporting Name Lists a shorter or abbreviated version of the Published Name for a test

mSMART Eval, PCPDs, FISH

Aliases Lists additional common names for a test, as an aid in searching

+1q or 1q22
+3/+7
+9/+15
-13 (monosomy 13)
13q- / -13 (13q deletion) or RB1
17p- (17p deletion) or TP53
IGH (14q32) rearrangement
Monoclonal Gammopathy of Undetermined Significance (MGUS)
Multiple Myeloma
MYC (8q24.1) rearrangement
Plasma Cell Leukemia
t(11;14) - CCND1/IGH
t(14;16) - IGH/MAF
t(14;20) - IGH/MAFB
t(4;14) - FGFR3/IGH
t(6;14) - CCND3/IGH